ABSTRACT
La hospitalización a domicilio (HAD) es una alternativa asistencial del Área de Salud de Pamplona consistente en un modelo organizativo capaz de dispensar a pacientes en su propiodomicilio un conjunto de actividades y cuidados sanitarios con complejidad, intensidad y duración comparables a los de una hospitalización convencional cuando todavía precisan de unavigilancia activa y una asistencia compleja. Ante el incremento progresivo de ingresos en el Hospital Universitario de Navarra (HUN) y lasprevisiones existentes para las siguientes semanas, el lunes 9 de marzo de 2020 se decide creardentro de la unidad de HAD del HUN una unidad específica centrada en COVID-19 y que, portanto, entra en el dispositivo de atención a los pacientes con infección por COVID-19. Debido al incremento progresivo en el número de ingresos hospitalarios, el día 26 de marzo elServicio Navarro de Salud-Osasunbidea (SNS-O) decide medicalizar el hotel Iruña Park con elobjetivo de incrementar el número de camas hospitalarias disponibles. En este documento se expone la actividad realizada en las tres primeras olas por la unidad deHAD del HUN en la atención domiciliaria y en la primera ola en el hotel medicalizado.(AU)
Subject(s)
Humans , Home Care Services, Hospital-Based , Hospitals, University , Pandemics , Coronavirus Infections/epidemiology , Spain , Public Health , Health ServicesABSTRACT
No disponible
Subject(s)
Humans , Coronavirus Infections/therapy , Pneumonia, Viral/therapy , Pandemics , Home Care Services, Hospital-Based/methods , Patient IsolationABSTRACT
BACKGROUND: Rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients with antiphospholipid syndrome is uncertain. METHODS: This randomised, controlled, open-label, phase 2/3, non-inferiority trial, done in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for previous venous thromboembolism, with a target international normalised ratio of 2·5. Patients were randomly assigned 1:1 to continue with warfarin or receive 20 mg oral rivaroxaban daily. Randomisation was done centrally, stratified by centre and patient type (with vs without systemic lupus erythematosus). The primary outcome was percentage change in endogenous thrombin potential (ETP) from randomisation to day 42, with non-inferiority set at less than 20% difference from warfarin in mean percentage change. Analysis was by modified intention to treat. Other thrombin generation parameters, thrombosis, and bleeding were also assessed. Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin generation. This trial is registered with the ISRCTN registry, number ISRCTN68222801. FINDINGS: Of 116 patients randomised between June 5, 2013, and Nov 11, 2014, 54 who received rivaroxaban and 56 who received warfarin were assessed. At day 42, ETP was higher in the rivaroxaban than in the warfarin group (geometric mean 1086 nmol/L per min, 95% CI 957-1233 vs 548, 484-621, treatment effect 2·0, 95% CI 1·7-2·4, p<0·0001). Peak thrombin generation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47-66 vs 86 nmol/L, 72-102, treatment effect 0·6, 95% CI 0·5-0·8, p=0·0006). No thrombosis or major bleeding were seen. Serious adverse events occurred in four patients in each group. INTERPRETATION: ETP for rivaroxaban did not reach the non-inferiority threshold, but as there was no increase in thrombotic risk compared with standard-intensity warfarin, this drug could be an effective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboembolism. FUNDING: Arthritis Research UK, Comprehensive Clinical Trials Unit at UCL, LUPUS UK, Bayer, National Institute for Health Research Biomedical Research Centre.
